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Dear Editor, 
 
We read with interest the various comments from Seeman and Nguyen [1]. Many of these are 
speculative interpretations of data about differences in bisphosphonates that may or may not 
be of clinical relevance. While of interest, we feel that the comments they make are in the 
most part irrelevant to our article [2]. However, they did raise a couple of issues that we 
would like to clarify 
 
We did not report the analysis of covariance as the purpose of our article was not to compare 
treatments, but rather to examine the definition and detection of responses to treatment in 
individuals. As we described, the response rates defined by bone turnover markers (BTM) 
were somewhat lower in the women receiving risedronate. This was also confirmed in an 
analysis of covariance; this mixed model ITT analysis did indeed use log-transformed data 
with baseline BTM as co-factor and ibandronate as the comparator for treatment effect. There 
remained a significant treatment effect for CTX and NTX (P<0.001); (the risedronate group 
was different to ibandronate whereas alendronate was not). Baseline BTM was significant for 
all BTM (BAP P=0.001, OC P=0.007, PINP, CTX and NTX, all P<0.001) in that those with 
higher baseline values experienced significantly greater decreases in the individual BTM. 
 
The correspondents misunderstand the origin of the terms µresorption¶ and µformation¶ 
markers. We don¶t have to assume that osteoclasts resorb bone and release collagen 
fragments or that osteoblasts secrete proteins such as osteocalcin.We know from in vitro 
studies that bone turnover markers are products of the work of bone cells [3]. They are 
not in any way surrogates of cellular activity; indeed, Seeman and Nguyen interpret the 
changes in BTM during early treatment in terms of the impact of treatment on cellular 
changes. However, we do not propose in our paper that we are able to use BTM to replace 
bone histomorphometry, nor that we can infer from the changes in their levels whether 
these changes are occurring in a particular bone envelope. We agree that it is appropriate 
to evaluate (but not define) bone turnover markers for their associations with bone 
turnover rates using radiotracer kinetics [4] or bone histomorphometry [5]. 
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